Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12405033 | 0.83 | BRD4 (0.37) | BRD4BRD2 | |
| SCHEMBL12028831 | 0.76 | — | — | |
| SCHEMBL12028834 | 0.74 | CYP2C9 (0.31) | — | |
| SCHEMBL27046535 | 0.73 | GRIN1 (0.41) | BRD4BRD2 | |
| SCHEMBL12405058 | 0.72 | GPBAR1 (0.33) | BRD4BRD2 | |
| SCHEMBL12658967 | 0.71 | GRIN1 (0.33) | BRD4BRD2 | |
| SCHEMBL12658975 | 0.71 | GRIN1 (0.38) | BRD4BRD2 | |
| SCHEMBL12028851 | 0.70 | SLC6A9 (0.34) | — | |
| SCHEMBL16750986 | 0.68 | GRIN1 (0.36) | — | |
| SCHEMBL16751010 | 0.68 | GRIN1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049845-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS | INNOVIVA TRC HOLDINGS LLC | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049845-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS | GRIN2A, GRIN3A, GRIN1 | BRD4 2452/4885BRD2 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.